Levetiracetam Eugia (Levetiracetam)

Levetiracetam is used to manage several seizure types within the broader category of epileptic disorders.

• Partial seizures: Reduces frequency of focal onset seizures, with or without secondary generalization.
• Generalized tonic‑clonic seizures: Controls convulsive seizures that involve the whole brain.
• Myoclonic seizures: Decreases sudden, brief muscle jerks characteristic of myoclonic epilepsy.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent exocytosis, stabilizing neuronal membranes and diminishing excessive synaptic firing. By reducing the release of excitatory neurotransmitters, the drug lowers neuronal excitability and helps prevent the initiation and propagation of seizure activity across cortical networks.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: generalized tiredness or lack of energy.
• Headache: mild to moderate cranial pain.
• Irritability: increased mood lability or agitation.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Mood or behavior changes: depression, suicidal thoughts, or aggression.
• Hematologic abnormalities: thrombocytopenia or leukopenia.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing or handling Levetiracetam Eugia, several precautions should be observed to ensure patient safety and product integrity.

• Renal function: Adjust dose in patients with impaired renal clearance.
• Pregnancy: Use only if potential benefit justifies potential risk, as safety data are limited.
• Concomitant CNS depressants: Monitor for additive sedation or dizziness.
• Psychiatric history: Observe for emergence of mood or behavioral disturbances.
• Administration: Infuse intravenously according to aseptic technique and recommended rate.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Carbamazepine: May reduce levetiracetam plasma levels, decreasing seizure control.
• Phenobarbital: Similar enzyme‑inducing effect that can lower levetiracetam concentrations.
• Rifampicin: Strong inducer that can markedly decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely)

• Sedative agents (e.g., benzodiazepines, opioids): May enhance central nervous system depression.
• Antidepressants (e.g., SSRIs): Potential for increased irritability or mood changes.
• Alcohol: Combined use can intensify dizziness and fatigue.